Wu Hao, Zhang Weiming, Wu Zhongxiao, Shen Yanna, Zhang Li, Yang Mouzhe, Ren Yougang, Mao Feng
Department of Dermatology, Ningbo No. 6 Hospital, Ningbo, China.
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China.
Postepy Dermatol Alergol. 2023 Dec;40(6):741-746. doi: 10.5114/ada.2023.132260. Epub 2024 Jan 8.
Dupilumab is the first biologic agent used to clinically treat moderate and severe atopic dermatitis (AD) and is currently the only biologic agent used for this condition. Many studies have reported that moderate-to-severe AD was significantly improved after dupilumab injection, although head/neck dermatitis occurred with itching, flushing, and scaling. Moreover, because all the symptoms occur after dupilumab treatment, they are called "dupilumab facial redness (DFR)".
To retrospectively analyse the clinical characteristics and treatment of facial erythema in patients with atopic dermatitis treated with dupilumab.
The clinical data of patients with moderate-to-severe atopic dermatitis treated with dupilumab (600 mg for the first time, 300 mg every 2 weeks thereafter) in the department of dermatology from July 2020 to May 2022 were obtained. We described their characteristics and analysed their symptomatic treatment measures and efficacy.
Twenty-one patients with DFR were included. Most clinical manifestations were erythema and pruritus, which differed from the symptoms of typical moderate-to-severe AD. After treatment, drug withdrawal, and dressing change, the symptoms of 17 patients were effectively controlled or completely improved, while these of 4 did not improve.
Although the mechanism of DFR is still unclear, symptomatic treatment is partially effective, and medication discontinuation and switching to Janus kinase inhibitors are acceptable for some patients.
度普利尤单抗是首个用于临床治疗中度和重度特应性皮炎（AD）的生物制剂，也是目前唯一用于该病症的生物制剂。许多研究报告称，注射度普利尤单抗后，中重度AD有显著改善，尽管头颈部皮炎会伴有瘙痒、潮红和脱屑。此外，由于所有这些症状都在度普利尤单抗治疗后出现，因此被称为“度普利尤单抗面部发红（DFR）”。
回顾性分析接受度普利尤单抗治疗的特应性皮炎患者面部红斑的临床特征及治疗情况。
获取2020年7月至2022年5月在皮肤科接受度普利尤单抗治疗（首次600mg，此后每2周300mg）的中重度特应性皮炎患者的临床资料。我们描述了他们的特征，并分析了他们的对症治疗措施及疗效。
纳入21例DFR患者。大多数临床表现为红斑和瘙痒，这与典型中重度AD的症状不同。经过治疗、停药和换药后，17例患者的症状得到有效控制或完全改善，而4例患者的症状未改善。
尽管DFR的机制尚不清楚，但对症治疗部分有效，对于一些患者而言，停药并改用 Janus激酶抑制剂是可行的。
